We scan new podcasts and send you the top 5 insights daily.
Greg Crescenzi says 90% of Addgene's COVID deposits and resources were made available to industry during the pandemic, enabling a faster collective response. Addgene now wants to extend that same industry access to much of its other translational material, not just crisis-specific reagents, according to him.
Malina Fan spent months trying to get plasmids, then realized depositing scientists wanted to share but lacked time and infrastructure. Greg Crescenzi says Addgene took over storage, logistics, legal agreements, QC, and curation, removing the burden from both requesters and institutions shipping materials so sharing could scale.
Industry partnerships are crucial for more than just funding. Collaborating with pharmaceutical companies provides translation-focused questions that guide the design of advanced cell models, ensuring they are predictive, scalable, and compatible with real-world development workflows.
Greg Crescenzi defines success as materials, methods, and even results flowing freely by default between academia and industry. Restricting access should be a conscious exception, he says. He also wants industry to share unpublished experiment information, including failures, because that knowledge is valuable to others.
Universities of Applied Sciences can mitigate the high cost of lab courses by sourcing nearly-expired or used materials from industry partners. Consumables like cell culture media and protein resins, which are no longer viable for regulated projects, are perfectly suitable and valuable for student training.
The company's mRNA and lipid nanoparticle (LNP) platform can leverage the massive manufacturing and distribution infrastructure built globally for COVID-19 vaccines. This solves a major scalability bottleneck that plagues traditional cell therapies, making their advanced treatment potentially as accessible and distributable as a vaccine.
Greg Crescenzi says Addgene's Solid Bio deal brings a therapeutic company's technology to academic and industry labs. Addgene already sells NEB and Promega products and wants more such partnerships, making reagent sharing flow from industry to academia as well as the reverse, according to him.
Greg Crescenzi says Addgene has received over 15,000 CRISPR plasmid deposits, including foundational materials, and those have generated 300,000 shipments to 5,000 organizations. That shipment volume shows how a central repository prevents many labs from separately rebuilding the same validated tools and wasting time and money.
Greg Crescenzi says Addgene holds historical, curated information that no one else has and is talking with software and AI companies about partnerships. He sees AI today as rapidly changing the space and wants Addgene's archive to support new data and information products, he says.
The innovation pipeline in biotech often starts in academia with fundamental breakthroughs like CRISPR or single-cell sequencing. Industry then provides the resources and engineering mindset to scale these technologies, robustify them, and generate the massive, high-quality datasets required to power AI-driven discovery.
Airway Therapeutics' CEO founded a CRO to resolve the disconnect between academic research's discovery focus and industry's market-driven goals. This "translator" model aligned incentives and regulatory understanding, fostering more efficient drug development by merging clinical feasibility with commercial targets.